Review of tegaserod in the treatment of irritable bowel syndrome

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 11, 2004, Pages 2369-2379

  Patel, Sonal ^a   Berrada, Driss ^a   Lembo, Anthony ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

5 HT4; Constipation; Irritable bowel syndrome(IBS); Tegaserod

Indexed keywords

ALOSETRON; AMINOGUANIDINE; CAPTOPRIL; CISAPRIDE; DEXTROMETHORPHAN; ERYTHROMYCIN; ESTRADIOL; FLUOXETINE; LAXATIVE; LOPERAMIDE; MACROGOL; METOCLOPRAMIDE; OMEPRAZOLE; OPIATE; PLACEBO; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTHROPATHY; BACKACHE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MILK LEVEL; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ECG ABNORMALITY; FLATULENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SECRETION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; HYPOVOLEMIA; INJURY; IRRITABLE COLON; LEG PAIN; MIGRAINE; MUSCULOSKELETAL DISEASE; NAUSEA; NONHUMAN; POSTMARKETING SURVEILLANCE; QT PROLONGATION; RETROSPECTIVE STUDY; REVIEW; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION; SYNCOPE;

ANIMALS; CLINICAL TRIALS, PHASE III; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; MALE; SEROTONIN AGONISTS;

EID: 8544257356     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.11.2369     Document Type: Review

References (63)

1. DROSSMAN DC, TALLEY N, THOMPSON W, WHITEHEAD W: Rome II: a multinational consensus document on functional gastrointestinal disorders. Gut (1999) 45(Suppl. II): 1-81.
2. SAITO YA, SCHOENFELD P, LOCKE GR 3rd: The epidemiology of irritable bowel syndrome in North America: a systematic review. Am. J. Gastroenterol. (2002) 97(8):1910-1915.
3. BOMMELAER G, ROUCH M, DAPOIGNY M et al.: Epidemiology of intestinal functional disorders in an apparently healthy population. Gastroenterol. Clin. Biol. (1986) 10(1):7-12.
4. DROSSMAN DA, MCKEE DC, SANDLER RS et al.: Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology (1988) 95(3):701-708.
5. THOMPSON WG, HEATON KW: Functional bowel disorders in apparently healthy people. Gastroenterology (1980) 79 2):283-288.
6. TALLEY NJ, GABRIEL SE, HARMSEN WS, ZINSMEISTER AR, EVANS RW: Medical costs in community subjects with irritable bowel syndrome. Gastroenterology (1995) 109(6):1736-1741.
7. FULLERTON S: Functional digestive disorders (FDD) in the year 2000 - economic impact. Eur. J. Surg. Suppl. (1998) 582 62-64.
8. CAMILLERI M, WILLIAMS DE: Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics (2000) 17(4)331-338.
9. PATEL RP, PETITTA A, FOGEL R, PETERSON E, ZAROWITZ BJ: The economic impact of irritable bowel syndrome in a managed care setting. J. Clin. Gastroenterol. (2002) 35(1):14-20.
10. GRALNEK IM, HAYS RD, KILBOURNE A, NALIBOFF B, MAYER EA: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology (2000) 119(3):654-660.
11. THOMPSON WG, LONGSTRETH GF, DROSSMAN DA et al.: Functional bowel disorders and functional abdominal pain. Gut (1999) 45(Suppl. 2):II43-II47.
12. KLEIN KB: Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology (1988) 95(1):232-241.
13. JACKSON JL, O'MALLEY PG, TOMKINS G et al.: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am. J. Med. (2000) 108(1):65-72.
14. AKEHURST R, KALTENTHALER E: Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut (2001) 48(2):272-282.
15. JAILWALA J, IMPERIALE TF, KROENKE K: Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann. Intern. Med. (2000) 133(2):136-147.
16. POYNARD T, REGIMBEAU C, BENHAMOU Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. (2001) 15(3):355-361.
17. BRANDT LJ, BJORKMAN D, FENNERTY MB et al.: Systematic review on the management of irritable bowel syndrome in North America. Am. J. Gastroenterol. (2002) 97(11 Suppl.):S7-S26.
18. KIM DY, CAMILLERI M: Serotonin: a mediator of the brain-gut connection. Am. J. Gastroenterol. (2000) 95(10):2698-2709.
19. GRIDER JR, FOXX-ORENSTEIN AE, JIN JG: 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology (1998) 115(2 ):370-380.
20. PFANNKUCHE HJ, BUHL T, GAMSE R et al.: The properties of a new prokinetically active drug SDZ HTF 919. Neurogastroenterol. Motil. (1995) 7:280.
21. BEATTIE D, ARMSTRONG S, HUMPHREY P et al.: Tegaserod is a potent 5-HT2B Antagonist in vitro and in vivo. (2004) (DDW Abstract).
22. APPEL S, KUMLE A, HUBERT M, DUVAUCHELLE T: First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist. J. Clin. Pharmacol. (1997) 37(3):229-237.
23. RIVKIN A. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review. Clin. Ther. (2003) 25 7):1952-1974.
24. APPEL-DINGEMANSE S, HIRSCHBERG Y, OSBORNE S, POMMIER F, MCLEOD J: Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). Eur. J. Clin. Pharmacol. (2001) 56(12):889-891.
25. APPEL-DINGEMANSE S, HOROWITZ A, CAMPESTRINI J, OSBORNE S, MCLEOD J: The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects - male and female, elderly and young. Aliment. Pharmacol. Ther. (2001) 15(7):937-944.
26. APPEL-DINGEMANSE S: Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. Clin. Pharmacokinet. (2002) 41(13):1021-1042.
27. VICKERS AE, ZOLLINGER M, DANNECKER R et al.: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab. Dispos. (2001) 29(10):1269-1276.
28. NGUYEN A, CAMILLERI M, KOST LJ et al.: SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J. Pharmacol. Exp. Ther. (1997) 280(3):1270-1276.
29. JI SW, PARK H, CHUNG JP, LEE SI, LEE YH: Effects of tegaserod on ileal peristalsis of Guinea pig in vitro. J. Pharmacol. Sci. (2004) 94(2):144-152.
30. DEGEN L, MATZINGER D, MERZ M et al.: Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment. Pharmacol. Ther. (2001) 15(11):1745-1751.
31. PETRIG C, TEMPLETON J, MATZINGER D et al.: Effect of tegaserod on gastrointestinal transit in male and female subjects. Gut. (2002) 51(Suppl. III):A138.
32. PRATHER CM, CAMILLERI M, ZINSMEISTER AR, MCKINZIE S, THOMFORDE G: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology (2000) 118(3):463-468.
33. STONER M, ARCUNI J, LEE J et al.: A selective 5-HT4 receptor agonist induces cAMP-mediated Cl efflux from rat colonocytes. Gastroenterology(1999) 116(4 Suppl. 2):A648.
34. WEBER E, BERNHARD M, PFANNKUCHE HJ: The 5-HT4 receptor agonist, tegaserod, stimulates electrolyte/water secretion in the rat colon. (2004) (DDW Abastract).
35. KELLOW JE, DELVAUX M, AZPIROZ F et al.: Principles of applied neurogastroenterology: physiology/motility-sensation. Gut (1999) 45(Suppl. 2):II17-II24.
36. FOXX-ORENSTEIN AE, KUEMMERLE JF, GRIDER JR: Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology (1996) 111 5):1281-1290.
37. BORNSTEIN JC, FURNESS JB, SMITH TK, TRUSSELL DC: Synaptic responses evoked by mechanical stimulation of the mucosa in morphologically characterized myenteric neurons of the guinea-pig ileum. J. Neurosci. (1991) 11(2):505-518.
38. SCHIKOWSKI A, THEWISSEN M, MATHIS C, ROSS HG, ENCK P: Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol. Motil. (2002) 14(3)221-227.
39. COELHO AM, ROVIRA P, FIORAMONTI J, BUENO L: Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist colorectal distension in rats. Gastroenterology (2000) 118 4):A835:4393.
40. COFFIN B, FARMACHIDI JP, RUEEGG P, BASTIE A, BOUHASSIRA D: Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment. Pharmacol. Ther. (2003) 17(4):577-585.
41. TACK J, VOS R, JANSSENS J et al.: Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment. Pharmacol. Ther. (2003) 18 10):1031-1037.
42. NOVICK J, MINER P, KRAUSE R et al.: A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. (2002) 16(11):1877-1888.
43. SHAH SH, JAFRI SW, GUL M et al.: Efficacy and tolerability of tegaserod in constipation dominant irritable bowel syndrome. J. Coll. Physicians Surg. Pak. (2004) 14(1 ):21-24.
44. WHORWELL PJ, KRUMHOLZ S, MULLER-LISSNER S et al.: Tegaserod has a favorable safety and tolerability profile in patients with constipation-predominant and alternating forms of irritable bowel syndrome. Gastroenterology (2000) 118:A1204.
45. MULLER-LISSNER SA, FUMAGALLI I, BARDHAN KD et al.: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol. Ther. (2001) 15 10):1655-1666.
46. LEFKOWITZ M, SHI Y, SCHMITT C, KRUMHOLZ S, TANGHE J: The 5-HT4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome (IBS). Am. J. Gastroenterol. (1999) 94(9):266.
47. LIN S, ZHOU H, XINGUANG L et al.: Tegaserod Provides rapid, effective relief of abdominal pain/discomfort, bloating and constipation in chinese patients with irritable bowel syndrome with constipation (Abstract). Gastroenterology (2003) 124:S1017.
48. KELLOW J, LEE OY, CHANG FY et al.: An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut (2003) 52(5):671-676.
49. NYHLIN H, BANG C, ELSBORG L et al.: A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand. J. Gastroenterol. (2004) 39(2):119-126.
50. RUEEGG P, SHI Y, KRUMHOLZ S et al.: Tegaserod, a partial 5-HT4 agonist, improves abdominal bloating and altered stool consistency in irritable bowel syndrome (IBS). Am. J. Gastroenterol. (1999) 94:A432 (Abstract).
51. EVANS BW, CLARK WK, MOORE DJ, WHORWELL PJ: Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. (2004): CD003960.
52. MORGANROTH J, RUEGG PC, DUNGER-BALDAUF C et al.: Tegaserod, a 5-hydroxytryptamine Type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am. J. Gastroenterol. (2002) 97(9):2321-2327.
53. DRICI MD, EBERT SN, WANG WX et al.: Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J. Cardiovasc. Pharmacol. (1999) 34(1):82-88.
54. BUSTI AJ, MURILLO JR Jr, CRYER B: Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy (2004) 24(4):526-531.
55. SCHOENFELD P: Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials. Aliment. Pharmacol. Ther. (2004) 19 3):263-269.
56. TOUGAS G, SNAPE WJ Jr, OTTEN MH et al.: Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. (2002) 16 10):1701-1708.
57. ZHOU H, KHALILIEH S, SVENDSEN K et al.: Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects. J. Clin. Pharmacol. (2001) 41(9):987-993.
58. KALBAG J, MIGOYA E, OSBORNE S et al.: Tegaserod does not significantly affect the pharmacokinetics of dextromethorphan in healthy subjects. Gastroenterology (2000) 118(4 Suppl. 2, Pt 2): A1179 (Abstract).
59. ZHOU H, WALTER Y, HUBERT M et al.: Tegaserod (HTF 919) does not decrease the effectiveness of an oral contraceptive when coadministered to healthy female subjects. Gastroenterology (2000) 118 (4 Suppl. 2, Pt 2): A1207 (Abstract).
60. LEDFORD P, ON N, LIGUEROS-SAYLAN M et al.: Tegaserod does not significantly affect the pharmacokinetics and pharmacodynamics of warfarin in healthy subjetcs. Gastroenterology (2000) 118 4 Suppl. 2, Pt 2):A1184 (Abstract).
61. CAMILLERI M: Review article: tegaserod. Aliment. Pharmacol. Ther. (2001) 15(3):277-289.
62. LONGSTRETH GF, WILSON A, KNIGHT K et al.: Irritable bowel syndrome, health care use, and costs: a US managed care perspective. Am. J. Gastroenterol. (2003) 98(3):600-607.
63. COLE JA, COOK SF, SANDS BE, AJENE AN, MILLER DP, WALKER AM: Occurrence of colon ischemia in relation to irritable bowel syndrome. Am. J. Gastroenterol. (2004) 99(3):486-491.